Stockholm, V7CIK 13818434 filings on record
Reported 13F value by quarter
Portfolio value trend — upgrade to see history
UpgradeLargest positions by weight
39 positions · Q4 2025
| # | Security | Shares | Value | % Port. | Δ Shares | Activity |
|---|---|---|---|---|---|---|
| 1 | Eli Lilly & Co | 31.1K | $33.46M | 10.7% | −6.1K | Reduced |
| 2 | Abbvie Inc | 108.2K | $24.72M | 7.9% | +16.1K | Added |
| 3 | Merck & Co Inc | 195.8K | $20.61M | 6.6% | +34.9K | Added |
| 4 | Thermo Fisher Scientific Inc |
| 29.9K |
| $17.33M |
| 5.5% |
| +2.8K |
| Added |
| 5 | Neurocrine Biosciences Inc | 94.8K | $13.44M | 4.3% | −7.8K | Reduced |
| 6 | Intuitive Surgical Inc | 22.3K | $12.64M | 4.0% | +2.6K | Added |
| 7 | Beone Medicines Ltd | 40.4K | $12.28M | 3.9% | +10.1K | Added |
| 8 | Bridgebio Pharma Inc | 141.3K | $10.81M | 3.4% | −33.4K | Reduced |
| 9 | Vertex Pharmaceuticals Inc | 23.0K | $10.42M | 3.3% | +5.2K | Added |
| 10 | Boston Scientific Corp | 108.7K | $10.36M | 3.3% | +22.0K | Added |
See this fund's complete portfolio, full position changes, and activity history.
Unlock full portfolio